DHHS Lists Rilpivirine as an Alternative NNRTI

Efavirenz is still the only preferred nonnucleoside reverse transcriptase inhibitor for initial treatment regimens.

On August 16, 2011, the U.S. Department of Health and Human Services (DHHS) issued supplemental recommendations regarding the role of rilpivirine in initial HIV treatment. Rilpivirine, a nonnucleoside reverse transcriptase inhibitor (NNRTI), was recently approved as a stand-alone product (JW AIDS Clin Care May 27 2011) and is also part of a newly approved one-pill, once-daily fixed-dose combination (JW AIDS Clin Care Aug 15 2011).

In these latest recommendations, efavirenz continues to be the only preferred NNRTI for initial treatment, and rilpivirine is listed as an alternative.

The panel's decision was based on a review of data from the ECHO and THRIVE trials, which directly compared efavirenz with rilpivirine (JW AIDS Clin Care Aug 1 2011)…

Reviewing Author

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

DHHS Lists Rilpivirine as an Alternative NNRTI

Topics

Reviewing Author